Ann: Zelda Enters Strategic Partnership with CannPal, page-4

I just put an investment in for MOH (merchant funds) last week, they have interests in Ac8, ZLD, MMJ, MXC and are interestingly taking CannPal to ASX.

Some information on CannPal

CannPal are setting themselves up as the leader in the cannabinoid-derived animal health sector, by working with regulators in both Australia and the United States. They expect to be the first animal health company to get FDA regulatory approval for a veterinary drug, and they’re set to begin clinical trials on their lead drug candidate targeting the symptomatic relief of Osteosarcoma Pain, in 2017. The hope is to extend that to palliative care for treating pain in a range of different cancers.
CannPal is differentiating itself from other cannabinoid-based animal health companies by focusing on regulatory approved medicines by providing veterinarians with the safety and efficacy studies that support standardized treatments.

CannPal has become the first animal health company to receive a sponsor fee waiver for a cannabinoid-derived treatment by the FDA’s Centre for Veterinary Medicine, in a giant step forward for the medical cannabis industry.
Under the minor use/minor species provision of the Animal Drug User Fee Act of 2003, CannPal applied for the fee waiver for its treatment of the symptomatic relief of Osteosarcoma pain. Osteosarcoma is a severely aggressive bone tumor in dogs and managing director Layton Mills is hopeful this is the beginning of a new standard of palliative care.
“Cancer pain is a debilitating side effect of an already terrible disease. Palliative care is often the last line of defense and there’s nothing that veterinarians can use that can offer a respectable quality of life in the remaining days of those diagnosed.”
The company hopes to expand the pain medication to be more accessible not just for cancer patients, but as a chronic pain treatment for both cats and dogs across a number of health conditions. The company has clinical trials planned to begin in 2017 under the guidance of world leading Osteosarcoma expert Dr Timothy Fan, and are excited to bring this new treatment to the veterinary world.

Some interesting statistics that may impact this industry locally, not even considering internationally:

There are an estimated more than 25 million pets in Australia. Dogs are the most common pet, with 39% of households owning a dog. There are estimated to be 4.2 million pet dogs in Australia; 19 dogs for every 100 people. Cats are the second most common pet, with 29% of households owning a cat.